D.E. Shaw & Co
INO icon

D.E. Shaw & Co’s Inovio Pharmaceuticals INO Stock Holding History

D.E. Shaw & Co’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,333
Closed -$928K – 4866
2021
Q1 		$928K Buy
+8,333
New +$1.1M ﹤0.01% 3176

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's INO Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Inovio Pharmaceuticals (INO) stake by 0.85% in Q1 2026, selling an estimated $31.3K and leaving 2,212,819 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #2381.

D.E. Shaw & Co first reported a position in INO in Q4 2014 and has held it in 38 quarters since. The position peaked at $29.9M in Q4 2021. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • D.E. Shaw & Co held 2,212,819 shares of Inovio Pharmaceuticals worth $3.85M as of Q1 2026.
  • D.E. Shaw & Co sold 18,992 Inovio Pharmaceuticals shares in Q1 2026, an estimated $31.3K.
  • Inovio Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2381 holding.
  • D.E. Shaw & Co first reported a position in Inovio Pharmaceuticals in Q4 2014 and has held it in 38 quarters since.
  • D.E. Shaw & Co's Inovio Pharmaceuticals position peaked at $29.9M in Q4 2021.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.